Research programme: kallikrein inhibitors - Vantia

Drug Profile

Research programme: kallikrein inhibitors - Vantia

Alternative Names: KKI; VA-KLK; VA118020; VA8020

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vantia Therapeutics
  • Class Small molecules
  • Mechanism of Action Kallikrein inhibitors; Tissue kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Diabetes mellitus; Hereditary angioedema; Inflammation; Respiratory tract disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in United Kingdom (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in United Kingdom
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hereditary-angioedema in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top